Abstract

Addressing persistent global health disparities requires prioritizing diverse representation in clinical trials as both a scientific necessity and an ethical obligation. Scientifically, diverse participation enables a more comprehensive understanding of how genetic, environmental, and socio-economic factors impact disease progression and treatment efficacy across populations. Ethically, it ensures equitable access to the benefits of medical research, particularly for populations historically marginalized or disproportionately burdened by disease.

This talk will explore: (1) the multifactorial drivers of diverse threatening conditions, with case studies in genetic conditions such as Crohn’s disease, Cystic Fibrosis, sickle cell disease, and cancer, as well as infectious diseases caused by parasites (e.g., Human African Trypanosomiasis and malaria), viruses, and bacteria; (2) the consequences of underrepresentation in clinical trials, including skewed data and ineffective or harmful treatments for certain populations; and (3) my faith and pioneering work in public health, underpinned by my contributions to evolutionary systems biology and translational research, and how it exemplifies the transformative potential of inclusive clinical practices and advancing precision medicine for all.